NCT03094949 is a NA clinical trial of Partial Nephrectomy in Renal Cell Carcinoma, sponsored by Chinese PLA General Hospital.

Who is sponsoring NCT03094949?

NCT03094949 is sponsored by Chinese PLA General Hospital.

What drugs are being tested in NCT03094949?

Interventions in NCT03094949: Partial Nephrectomy, microwave ablation.

What condition does NCT03094949 study?

NCT03094949 studies Renal Cell Carcinoma.

Is NCT03094949 still recruiting?

NCT03094949 is currently status unknown. Last updated 29 March 2017.

Last reviewed 2017-03-29 · How we verify

NCT03094949

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison Between Partial Nephrectomy and Ablation for Renal Tumor

Status unknown NA Last updated 29 March 2017

What this trial tests

NA trial testing Partial Nephrectomy in Renal Cell Carcinoma in 200 participants. Status unknown.

Timeline

1 July 2008

Primary endpoint
1 July 2017

1 September 2017

Quick facts

Lead sponsor	Chinese PLA General Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	200
Start date	1 July 2008
Primary completion	1 July 2017
Estimated completion	1 September 2017
Sites	1 location across China

Drugs / interventions tested

Partial Nephrectomy
microwave ablation

Conditions studied

Renal Cell Carcinoma — all drugs for Renal Cell Carcinoma →

Sponsor

Chinese PLA General Hospital

Who can join

Eligibility, any sex, with Renal Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The therapeutic effectiveness of ultrasound guided cooled-probe microwave ablation and laparoscopic partial nephrectomy on T1a renal cell carcinoma is compared to find a better approach for renal tumor.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Current Management of Small Renal Masses, Including Patient Selection, Renal Tumor Biopsy, Active Surveillance, and Thermal Ablation.
Sanchez A, Feldman AS, Hakimi AA. · · 2018 · cited 110× · PMID 30372390 · DOI 10.1200/jco.2018.79.2341
Role of Podoplanin (PDPN) in Advancing the Progression and Metastasis of Glioblastoma Multiforme (GBM).
Sharma B, Agriantonis G, Shafaee Z, Twelker K, et al · · 2024 · cited 4× · PMID 39682237 · DOI 10.3390/cancers16234051
Are the long-term outcomes of percutaneous ablation for clinical stage T1 renal tumors similar to those of partial nephrectomy?
Mano R, Hakimi AA. · · 2019 · PMID 32016088 · DOI 10.21037/atm.2019.08.106

Verify or expand the search:

Other recruiting trials for Renal Cell Carcinoma

Currently open trials in the same condition.

NCT07397611 — Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC · Phase 2 · recruiting
NCT07195682 — A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) · Phase 1 · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT07227402 — A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6 · Phase 3 · recruiting
NCT07123090 — A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma · Phase 2 · recruiting

Other Chinese PLA General Hospital trials

Trials by the same sponsor.

NCT07294755 — The Impact of Intrapleural Block on Postoperative Pain Caused by Drainage Tubes After Thoracoscopic Surgery · NA · not yet recruiting
NCT07536607 — Predictive Role of Photon Counting Computed Tomography in Acute Coronary Syndrom Patients · not yet recruiting
NCT07489157 — Real-Time End-Tidal Carbon Dioxide Monitoring for Early Warning of Hypoxemia in Painless Gastrointestinal Endoscopy · NA · not yet recruiting
NCT07494981 — Individualized Precision Therapy With Ceftazidime and Avibactam Guided by PK/PD in Geriatric Populations · not yet recruiting
NCT07496008 — Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03094949 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese PLA General Hospital
Last refreshed: 29 March 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03094949.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing